Spire Wealth Management’s Nuvectis Pharma NVCT Stock Holding History

Spire Wealth Management’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-300	Closed	-$2.32K	–	2329
2026 Q1	$2.32K	Hold	300	–	–	﹤0.01%	2016
2025 Q4	$2.27K	Buy	+300	New	+$1.96K	﹤0.01%	2073

Other funds holding NVCT

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Austin Wealth Management Austin, Texas $473M AUM 18.73% 1-Year Est. Return

NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Spire Wealth Management's NVCT Position: Q2 2026 in Review

Spire Wealth Management sold out of Nuvectis Pharma (NVCT) in Q2 2026, closing a stake of 300 shares — an estimated $2.32K sold.

Spire Wealth Management first reported a position in NVCT in Q4 2025 and held it in 2 quarters. The position peaked at $2.32K in Q1 2026. 9 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

Spire Wealth Management reported no remaining Nuvectis Pharma position as of Q2 2026 after selling out during the quarter.
Spire Wealth Management sold 300 Nuvectis Pharma shares in Q2 2026, an estimated $2.32K.
Spire Wealth Management first reported a position in Nuvectis Pharma in Q4 2025 and held it in 2 quarters.
Spire Wealth Management's Nuvectis Pharma position peaked at $2.32K in Q1 2026.
9 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Spire Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.